

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10758307	
	Filing Date		2004-01-14	
	First Named Inventor	Melody A. Cobleigh		
	Art Unit	1636		
	Examiner Name	Celine X. Qian		
Attorney Docket Number		GHDX-008		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10758307
Filing Date	2004-01-14
First Named Inventor	Melody A. Cobleigh
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	GHDX-008

1	BERTUCCI, F., et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Human Molecular Genetics. 2000, vol. 9, no. 20, pp. 2981-1991.	<input type="checkbox"/>
2	CHENARD, M., et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. International Journal of Cancer. 1996, vol. 69, pp. 448-451.	<input type="checkbox"/>
3	ENGEL, G., et al. Correlation between stromelysin-3 mRNA and outcome of human breast cancer. International Journal of Cancer. 1994, vol. 58, pp. 830-835.	<input type="checkbox"/>
4	KONONEN, J., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine. 1998, vol. 4, no. 7, pp. 844-847.	<input type="checkbox"/>
5	VAN DE VIJVER, M., et al. A gene-expression signature as a predictor of survival in breast cancer. The New England Journal of Medicine. 2002, vol. 347, no. 25, pp. 1999-2009.	<input type="checkbox"/>
6	VAN'T VEER, L., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, vol. 415, pp. 530-536.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.